FDA Advisory Committee Rejects Combination Vaccine

Article

ATLANTA, Ga-An advisory committee has narrowly rejected to recommend a combination vaccine for children after questioning the vaccination's immunogenicity.

Infanrix, manufactured by GlaxoSmithKline, was voted down by a 6-5 vote. There was one abstention.

The vaccine is designed to guard against five common childhood diseases: diphtheria, whooping cough, tetanus, hepatitis B, and polio. The panel said the vaccine would not be recommended to the FDA because they questioned its effectiveness in creating a protective immune response.

The advisory panel's decision is not final; although, it is strongly considered by the FDA when approving new drugs.

A spokesperson for GlaxoSmithKline said the company is confident Infanrix would ultimately be approved.

Newsletter

Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.

Recent Videos
 Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
 Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
In a recent discussion with Infection Control Today® (ICT®), study authors Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio, shared their insights on how the project evolved and what the findings mean for the future.